Sigma-Aldrich's Q3 Sales Dip 1 Percent, but EPS Rises 9 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Sigma-Aldrich today reported that its third-quarter revenues dipped 1.3 percent year over year, with growth in its Research Biotech and fine chemicals (SAFC) businesses being offset by declines in its other units.

The chemicals and lab products firm generated total revenues of $533.8 million for the three-month period ended Sept. 30, compared to revenues of $540.6 million for the third quarter of 2008. Excluding the negative impact of currency translation, Sigma-Aldrich's sales grew around 2 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.